Molecular basis of triple negative breast cancer and implications for therapy. - Wikidata - wikimedia - TriplyDB

Molecular basis of triple negative breast cancer and implications for therapy.

Molecular basis of triple negative breast cancer and implications for therapy.

http://www.wikidata.org/entity/Q35684581

about

MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer Novel genes associated with lymph node metastasis in triple negative breast cancer Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis.The impact of Thr91 mutation on c-Src resistance to UM-164: molecular dynamics study revealed a new opportunity for drug design.Wnt signaling in triple negative breast cancer is associated with metastasis Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer Cdc20 and securin overexpression predict short-term breast cancer survival.PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis Cancer progression modeling using static sample data Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells A molecular analysis provides novel insights into androgen receptor signalling in breast cancer.MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.MixChIP: a probabilistic method for cell type specific protein-DNA binding analysis.Racial differences in outcomes of triple-negative breast cancer PKCζ Promotes Breast Cancer Invasion by Regulating Expression of E-cadherin and Zonula Occludens-1 (ZO-1) via NFκB-p65.An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6.Gold Nanoantenna-Mediated Photothermal Drug Delivery from Thermosensitive Liposomes in Breast Cancer.New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer.5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cells Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets.CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.Breast tumor subgroups reveal diverse clinical prognostic power.Triple-negative breast cancer: future prospects in diagnosis and management.The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.Double gene siRNA knockdown of mutant p53 and TNF induces apoptosis in triple-negative breast cancer cells.Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis.Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors.Theranostic Gold Nanoantennas for Simultaneous Multiplexed Raman Imaging of Immunomarkers and Photothermal Therapy Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery.Morgana acts as a proto-oncogene through inhibition of a ROCK-PTEN pathway.Anti-tumorigenic effects of a novel digitoxin derivative on both estrogen receptor-positive and triple-negative breast cancer cells.EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.Emergence of a Promising Lead Compound in the Treatment of Triple Negative Breast Cancer: An Insight into Conformational Features and Ligand Binding Landscape of c-Src Protein with UM-164.Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer.Establishment of two basal-like breast cancer cell lines with extremely low tumorigenicity from Taiwanese premenopausal women.

P2860

Q26775086-97F4EDD3-83C3-40A0-BF1B-B6FB5C7A69C0 Q28066481-55D9FD70-2F4B-44BD-9B59-ECC2E127E1DC Q28393204-EF71CDAD-BE0A-4E8A-B74F-13B4B8338EBF Q30009828-CF1DA64F-8722-42F6-BEAF-D64FA2E00CA9 Q30401596-8D9FA571-7212-4DE0-912D-A53638782926 Q30597238-08697F95-1D6E-44C5-AFC9-D042EEF2F91C Q33703293-A3F72C9A-952F-4521-BC5F-F97790839F61 Q33750165-CB15089F-B84D-4B1F-B212-5BC0F1E9AA7E Q34038395-DF786102-E15C-4F9C-B9C7-61C44B334154 Q34334159-548B4513-66A2-40DE-8020-2E1BE4705BAF Q34447273-5CE4135D-C3E2-42BB-A0A9-3373D6B52A4D Q35189443-AA3FE2D9-EEA1-4751-BF33-6F3EABBF59CC Q35719862-02D16921-1652-417B-BCE3-6C15C1D24661 Q35878429-295690AF-6367-437F-A9FF-9132FA20B924 Q35956986-F8E1993D-2D58-415C-85E8-3B0F46315B67 Q36288745-6C02551B-7F66-436A-9595-6C636D139E1D Q36315707-9D413AF2-069A-4F48-AA01-BA64698EA175 Q36545926-B640D9AA-7002-41C2-9925-0E86635F3FC8 Q37262447-5E80294D-CAAD-4420-B9F0-E7F677406689 Q37269463-8660C669-A7CD-4A64-87CE-2741DB7EEC53 Q37304764-1DDA0F07-9842-42E0-9F4C-C8BD97B8B48E Q37438076-11B6956D-7605-4CCA-8486-25371070C741 Q37536500-8DDDA8EF-C9F2-46AC-B49D-A0C7EE5396A2 Q37605645-7E7D422E-3022-413A-9136-671B2E1791AE Q37687393-66FA6677-BC0A-49E1-A1AF-041B89B27E7D Q37690966-B4083BFC-2830-49CE-8E0F-AEB7F913CECF Q37736572-1C0CF91D-551A-42D3-9ADA-58AC2BDA6DEF Q38175844-A4E21D3F-8FEA-406F-8C2D-0747410002D2 Q38712750-72750B59-1669-4452-899C-7DE0379A3A48 Q38726515-0F0CB0B8-4B16-4916-8377-8C5B33309DE6 Q38875037-2137B568-7AC4-4DF3-803F-5592D48D22C9 Q38887164-C6705C55-92EA-40CF-BB14-CDDA88F306BE Q41194394-9CEEFC82-2F2E-4D4A-9ECC-EDBE9411238F Q41320378-F19BE6AC-4370-4747-AB3A-96828BD4EE2A Q42805535-5E8CE4C8-C231-4B30-A8B6-08DCD9B6C594 Q46349486-B51FFD33-7076-4703-BE57-C18BC83A8723 Q47107525-6D46EA59-6F6C-451E-B509-F0E63CF422A3 Q47250599-2FD4B7EF-44D2-492C-B275-308DBF4E7D70 Q47311101-FED56565-2CAC-40D1-92A6-BB19C0F3C3A4 Q52730161-6395C67B-FFD5-4989-A60E-8ACE8999F3C1

P2860

Molecular basis of triple negative breast cancer and implications for therapy.

http://www.wikidata.org/entity/Q35684581

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Molecular basis of triple negative breast cancer and implications for therapy.

@ast

Molecular basis of triple negative breast cancer and implications for therapy.

@en

type

label

Molecular basis of triple negative breast cancer and implications for therapy.

@ast

Molecular basis of triple negative breast cancer and implications for therapy.

@en

prefLabel

Molecular basis of triple negative breast cancer and implications for therapy.

@ast

Molecular basis of triple negative breast cancer and implications for therapy.

@en

P1433

Q35684581-B26536BA-7100-42FC-B758-B3996C16FDB6

P1476

Q35684581-4575C782-27EE-4D5F-8664-DADA9F03382C

P2093

Q35684581-11D3814D-88B0-40E5-99A1-FE4656C376B5

Q35684581-5A013DC3-8B45-418D-B4B1-2D6D4136BA63

Q35684581-8AC0858A-16DA-4B62-A103-3CF8ED927110

P2860

Q35684581-054431FB-F664-4679-83FB-516DDE8FA86B

Q35684581-0CFB5FB7-3584-4B0C-ABA9-4F6DE4716F50

Q35684581-15849015-34B5-42D6-9795-1E3E902EA216

Q35684581-1705AEBE-BBD7-456E-B8FE-370A8B030610

Q35684581-1F79D233-2D0F-4E75-BE6B-367C6A797B70

Q35684581-1F897459-6C4B-43CD-853F-846EFE461A25

Q35684581-221CC791-15D8-48E3-ABC7-CC8E15210597

Q35684581-25796139-C9E0-4D98-8E54-0D5D9121859E

Q35684581-38714CFF-42E8-46B3-8C27-C83A7209D420

Q35684581-3AA33F58-AA36-4882-B890-9F258D94BD5A

P304

Q35684581-66AF97C1-D310-4CE2-B777-0D61D71EEE51

P31

Q35684581-FDC5809F-932F-461A-BF06-93E3CA0B2AFD

P356

Q35684581-EB28944B-1BF5-4DE6-9DEB-7EE940E3C079

P478

Q35684581-577BC7C6-1F00-48F5-9C81-9F97C2E5EB4B

P577

Q35684581-AACE9D20-CDE7-4EBB-B976-8DE474221FF8

P5875

Q35684581-133B3904-92E0-484F-8C28-F5C202BB2709

P698

Q35684581-03420BCC-AF9C-4546-B39B-60E568DFE6EB

P932

Q35684581-D66C462C-D016-408E-95AE-58FEB1DAC847

P356

P1433

International Journal of Breast Cancer

P1476

Molecular basis of triple negative breast cancer and implications for therapy.

@en

P2093

Cynthia Ma

http://www.w3.org/2001/XMLSchema#string

Matthew J Ellis

http://www.w3.org/2001/XMLSchema#string

Parvin F Peddi

http://www.w3.org/2001/XMLSchema#string

P2860

Recurring mutations found by sequencing an acute myeloid leukemia genome

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

X chromosomal abnormalities in basal-like human breast cancer

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

Genome remodelling in a basal-like breast cancer metastasis and xenograft

Triple-Negative Breast Cancer

Supervised risk predictor of breast cancer based on intrinsic subtypes

P304

217185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/217185

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221796409

http://www.w3.org/2001/XMLSchema#string

P698

22295242

http://www.w3.org/2001/XMLSchema#string

P932

3262606

http://www.w3.org/2001/XMLSchema#string